Mostly Markets
Subscribe
Markets
S&P 500 ▼ 1.82%Nasdaq ▼ 2.86%Dow ▼ 1.09%Russell 2000 ▼ 1.66%10-year 4.93%Oil ▲ 0.93%Gold ▼ 3.63%Bitcoin ▲ 1.13%
Newest story
Stocks/Health Care/Life Sciences Tools & Services

DanaherDHR

Life Sciences Tools & Services · Washington, D.C. · In the S&P 500
Solid businessPricier than peers
$232.23−2.00%After hours: $233.00 (+0.33%)At the close, 30 Oct · Prices from CNBC, may be delayed
▲ 8.5% over 1 year
Danaher over 1 yearDaily close, $, to 30 Oct 2026
$175$200$225Nov2026MarMayJulSep$232.23$200NovMarJul$232.23
Source: Nasdaq daily closes
Market value$163B
Price to earnings38.4x
Forward P/E26.5x
Dividend yield0.69%
Year to date+1.4%
One year+8.5%
Next earningsNot scheduled
SectorHealth Care
52-week range (closes)
$161.91$242.05

The latest on Danaher

Our stories first, then the headlines that could move it, newest first.

We haven't written about Danaher yet. Follow it, and its first story will show under My stocks.

Quality and valuation

How Danaher compares with other health care stocks. A description, not a recommendation.

Danaher and 7 life sciences tools & services peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: about averageValuation: pricier than most

An average business among health care companies, priced above most of them.

Danaher trades at 26.5 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew slower than the sector median: +5.5% vs +7.8%
  • Keeps less of each sale (gross margin): 58.6% vs 65.3%
  • More profitable (operating margin): 20.4% vs 13.3%
  • Turns more of its sales into cash: 22.4% vs 15.9%
DHR trades at 26.5x forward earnings, above the sector medianForward p/e, Life Sciences Tools & Services peers
IQV19.8xDHR26.5xTMO26.6xA26.6xCRL29.1xWAT29.8xMTD34.1xILMN41.6xSector median 19.1xIQV19.8xDHR26.5xTMO26.6xA26.6xCRL29.1xWAT29.8xMTD34.1xILMN41.6xSector median 19.1x
Source: CNBC quotes; Mostly Markets
At 38.0x earnings, DHR is cheaper than its average since Oct 2024Price over the last 12 months of reported (GAAP) diluted EPS
P/EUsual range (±1 s.d.)
35x40x45x50xAverage 40.7x2025202638.0x40x50xAverage 40.7x2025202638.0x
Source: Nasdaq prices; SEC filings

Financials

From Danaher's SEC filings, through the quarter ending 25 Sep 2026. Hover or tap a bar for its value.

Revenue grew 8.3% from a year earlierQuarterly revenue, $bn, latest Q3 ’26
$0bn$2bn$4bn$6bnQ4 ’24Q2 ’25Q4 ’25$6.5bnQ3 ’26$0bn$2bn$5bnQ4 ’24Q2 ’25Q4 ’25$6.5bnQ3 ’26
Source: SEC filings
Growth sped up to +8.3% last quarterRevenue growth, year on year, %
0%2%5%8%Q4 ’24Q2 ’25Q4 ’258.3%Q3 ’260%5%Q4 ’24Q2 ’25Q4 ’258.3%Q3 ’26
Source: SEC filings
Operating margin was 19.0% last quarterOperating income as a share of revenue, %
0%10%20%Q4 ’24Q2 ’25Q4 ’2519.0%Q3 ’260%10%20%Q4 ’24Q2 ’25Q4 ’2519.0%Q3 ’26
Source: SEC filings
Free cash flow was $5.7 billion over 12 monthsQuarterly free cash flow (operating cash flow minus capex), $bn
$0.0bn$0.5bn$1.0bn$1.5bnQ4 ’24Q2 ’25Q4 ’25$1.6bnQ3 ’26$0bn$1bnQ4 ’24Q2 ’25Q4 ’25$1.6bnQ3 ’26
Source: SEC filings
Last 12 monthsDHRSector median
Revenue growth+5.5%+7.8%
Gross margin58.6%65.3%
Operating margin20.4%13.3%
Free cash flow margin22.4%15.9%
Price to earnings38.4x30.2x

Similar companies

Life Sciences Tools & Services, by market value.

CompanyPriceTodayYTDValue
TMOThermo Fisher Scientific$697.00−1.72%+20.3%$258B
AAgilent Technologies$174.87−3.47%+28.5%$49.30B
WATWaters$462.72−3.61%+21.8%$45.46B
IQVIQVIA$267.33−2.81%+18.6%$44.06B
ILMNIllumina$235.99−18.64%+79.9%$35.63B
MTDMettler Toledo$1,674.81−2.55%+20.1%$33.56B
CRLCharles River Laboratories$359.41−4.44%+80.2%$17.16B
TECHBio-Techne$72.66−0.07%+23.6%$11.41B